HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
21 hedge funds and large institutions have $14.5M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 4 closing their positions.
9% less funds holding
Funds holding: 23 → 21 (-2)
12% less capital invested
Capital invested by funds: $16.4M → $14.5M (-$1.93M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
88% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.4K |
| 2 |
JP Morgan Chase
New York
|
+$116 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPA
Cowen Prime Advisors
New York
|
-$511K |
| 2 |
SC
Samjo Capital
New York
|
-$340K |
| 3 |
Millennium Management
New York
|
-$90K |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$59K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$19K |
HTGM Hedge Fund Activity: Q4 2021 in Review
21 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q4 2021, worth a combined $14.5M — down 12% from $16.4M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of HTGM and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 1 added.
The largest buyer was BlackRock, adding an estimated $1.4K. The largest seller was Cowen Prime Advisors, cutting an estimated $511K.
- 21 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q4 2021, down from 23 in Q3 2021.
- Funds reported $14.5M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q4 2021, down 12% quarter-over-quarter.
- 3 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q4 2021 and 4 closed out, a net change of -1 holder.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q4 2021 was BlackRock, an estimated $1.4K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q4 2021 was Cowen Prime Advisors, an estimated $511K sold.
Based on aggregated 13F filings for Q4 2021.